Holen Sie sich die Stockscreener-App
6.40
0.79%
0.05
Handel nachbörslich:
6.39
-0.01
-0.16%
Schlusskurs vom Vortag:
$6.35
Offen:
$6.28
24-Stunden-Volumen:
860.46K
Relative Volume:
0.95
Marktkapitalisierung:
$320.66M
Einnahmen:
$124.00K
Nettoeinkommen (Verlust:
$-49.99M
KGV:
-3.787
EPS:
-1.69
Netto-Cashflow:
$-31.03M
1W Leistung:
+7.38%
1M Leistung:
+10.15%
6M Leistung:
-27.44%
1J Leistung:
+9.59%
1-Tages-Spanne:
$6.11
$6.48
1-Wochen-Bereich:
$5.74
$6.48
52-Wochen-Spanne:
$3.785
$14.60
Candel Therapeutics Inc Stock (CADL) Company Profile
Firmenname
Candel Therapeutics Inc
Sektor
Branche
Telefon
617-916-5445
Adresse
117 KENDRICK STREET, NEEDHAM
Vergleichen Sie CADL mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CADL
Candel Therapeutics Inc
|
6.40 | 311.14M | 124.00K | -49.99M | -31.03M | -1.69 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.92 | 96.01B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.55 | 57.86B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.52 | 57.02B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
646.60 | 39.10B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
307.51 | 34.45B | 3.81B | -644.79M | -669.77M | -6.24 |
Candel Therapeutics Inc Stock (CADL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-30 | Fortgesetzt | H.C. Wainwright | Buy |
| 2025-02-20 | Eingeleitet | Citigroup | Buy |
| 2025-02-19 | Eingeleitet | Canaccord Genuity | Buy |
| 2025-02-07 | Eingeleitet | BofA Securities | Buy |
| 2022-12-02 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-11-19 | Eingeleitet | BMO Capital Markets | Outperform |
| 2021-08-23 | Eingeleitet | Credit Suisse | Outperform |
| 2021-08-23 | Eingeleitet | Jefferies | Buy |
| 2021-08-23 | Eingeleitet | UBS | Buy |
Alle ansehen
Candel Therapeutics Inc Aktie (CADL) Neueste Nachrichten
Candel Therapeutics Inc. Stages Intraday Comeback — Trend ChangeReal Trader Watchlist of Hot Stocks Released - beatles.ru
Candel Therapeutics CADL 2025Q2 Earnings Preview Downside Ahead on Lack of Revenue Data - AInvest
Cancer Vaccines Market to Show Remarkable Growth Trends from 2024 to 2034, DelveInsight Reports | Dendreon Pharma, Candel Therapeutics, GlaxoSmithKline, Merck, Aduro Biotech, Astrazeneca Plc, Dendreon - The Globe and Mail
Candel Therapeutics Institutional Ownership Soars to 44%: Implications for Stock Price Sensitivity - AInvest
Candel Therapeutics shares fall 2.76% intraday after announcing clinical trial initiation for tecarfarin in dialysis patients. - AInvest
How strong is Candel Therapeutics Inc. company’s balance sheetAchieve explosive financial results today - Jammu Links News
What are the latest earnings results for Candel Therapeutics Inc.Achieve consistent double-digit growth - Jammu Links News
What are Candel Therapeutics Inc. company’s key revenue driversCapitalize on market trends early - Jammu Links News
Is it the right time to buy Candel Therapeutics Inc. stockMaximize profits with strategic stock selection - Jammu Links News
How many analysts rate Candel Therapeutics Inc. as a “Buy”Dynamic investment growth - Jammu Links News
What catalysts could drive Candel Therapeutics Inc. stock higher in 2025Phenomenal returns - Jammu Links News
Candel Therapeutics Inc. Stock Analysis and ForecastUnlock powerful portfolio management tools - Jammu Links News
Is Candel Therapeutics Inc. stock overvalued or undervaluedFree Technical Analysis Support - Jammu Links News
What makes Candel Therapeutics Inc. stock price move sharplyGain the edge with real-time market data - Jammu Links News
Is Candel Therapeutics Inc. a growth stock or a value stockFree Stock Data Feed Backed By Experts - jammulinksnews.com
Candel Therapeutics (CADL) Upgraded to Strong Buy: Here's What You Should Know - MSN
Applying Wyckoff theory to Candel Therapeutics Inc. stockTop Gaining Picks With Entry Signals Identified - metal.it
Candel Therapeutics CMO Garrett Buys, Sells Shares Amid Company's Market Performance. - AInvest
Candel Therapeutics to Present at the Canaccord Genuity 45th Annual Growth Conference - GlobeNewswire
Why Candel Therapeutics Inc. stock attracts strong analyst attentionMomentum Based Equity Trading Plans Reviewed - beatles.ru
Candel Therapeutics to share company update at Canaccord Genuity Growth Conference - Proactive financial news
Candel Therapeutics CEO Dr. Tak to Share Cancer Immunotherapy Progress at Major Growth Conference - Stock Titan
Is Candel Therapeutics Inc. Stock a Good Fit for Conservative InvestorsAI Driven Buy Alert Trade Blueprint Released - metal.it
Published on: 2025-07-29 16:45:46 - metal.it
What machine learning models say about Candel Therapeutics Inc.Swing Trading Entry Signals Suggest Opportunity Zone - metal.it
Options Data Show Bullish Bias in Candel Therapeutics Inc.High Conviction Intraday Stock Signals Detected - beatles.ru
How does Candel Therapeutics Inc. generate profit in a changing economyNavigate market shifts with confidence - jammulinksnews.com
What is Candel Therapeutics Inc. company’s growth strategyExceptional market positioning - Jammu Links News
Will Candel Therapeutics Inc. Stock Benefit from AI and Green Energy TrendsTechnical Breakout List - metal.it
What is the dividend policy of Candel Therapeutics Inc. stockAchieve consistent profits with proven methods - Jammu Links News
What are the technical indicators suggesting about Candel Therapeutics Inc.Massive profits - jammulinksnews.com
What drives Candel Therapeutics Inc. stock priceFree Real-Time Stock Data - PrintWeekIndia
What analysts say about Candel Therapeutics Inc. stockMarket-leading profit generation - Autocar Professional
Is Candel Therapeutics Inc. a good long term investmentExplosive returns - PrintWeekIndia
Candel Therapeutics Receives EMA Orphan Designation for CAN-2409 for the Treatment of Pancreatic Cancer - GlobeNewswire
Candel Therapeutics' CAN-2409 Receives European Orphan Designation for Pancreatic Cancer Treatment - citybuzz -
Can Candel Therapeutics Inc. stock recover from recent declineExceptional return forecasts - jammulinksnews.com
Small cap wrap: Blockmate Ventures, Candel Therapeutics, HIVE Digital, American Resources... - Proactive financial news
Candel Therapeutics Gets European Orphan Status for Pancreatic Cancer Drug CAN-2409 - citybiz
Candel Therapeutics receives EMA Orphan Designation for immunotherapy candidate CAN-2409 - Proactive financial news
Finanzdaten der Candel Therapeutics Inc-Aktie (CADL)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.67%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):